CD68 and neoplasm: Thus, in the near future, multiple diagnostic assessments measuring or quantifying HIF-1α, CAIX, mTor or CD68/CD163 balance in tumor specimens and/or plasmatic samples might be proposed during the OTS patient journey to evaluate outcome risks.